HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

NCT07699757 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2026-07-14

No results posted yet for this study

Summary

This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors. The study consists of dose-escalation and dose-expansion parts and is intended to evaluate the safety, tolerability, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HSK41959 tablets when used together with standard therapy.

Conditions

Interventions

DRUG

HSK41959

Oral administration, QD

DRUG

Sintilimab

Specified dose on specified days

DRUG

Pemetrexed + Cisplatin /Carboplatin

Specified dose on specified days

DRUG

Paclitaxel + Carboplatin

Specified dose on specified days

DRUG

Nab-paclitaxel + Carboplatin

Specified dose on specified days

DRUG

Nab-paclitaxel + Gemcitabine

Specified dose on specified days

DRUG

Docetaxel

Specified dose on specified days

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-04-30
Completion
2029-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07699757 on ClinicalTrials.gov